ARS Pharmaceuticals, Inc.
NASDAQ:SPRYBiotechnology
-$0.35 today
- Market cap
- $370.95M
- Beta
- 0.83
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.99
Volume 1.70M
Average 1.67M
Returns on capital
ARS Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-149.9%
avg 27.5%
ROIC
-62.2%
avg -56.6%
ROA
-52.3%
avg -42.5%
Analysis
ROA is currently the strongest return metric at -52.3% versus its period average of -42.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Brian T. Dorsey | Chief Operations Officer | USD 706.97K | 57 | — | — |
Justin Chakma | Chief Business Officer | USD 682.7K | 36 | 240.00K | 0.24% |
Alexander A. Fitzpatrick | Chief Legal Officer & Secretary | USD 677.15K | 59 | 90.91K | 0.09% |
Eric Karas | Chief Commercial Officer | USD 618.61K | 53 | 12.18K | 0.01% |
Daniel Relovsky | Senior Vice President of Marketing | — | — | — | — |
Donn Casale | CEO, President & Director | — | 53 | 1.04M | 1.04% |
Kathleen D. Scott | Chief Financial Officer | — | — | 240.00K | 0.24% |
Lynda Harris | Vice President of Human Resources | — | — | — | — |
Robert Bell | Co-Founder & Chief Science Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$283,550.00
Net Transaction Value
−$283,550.00
Net selling
Most Active
Karas Eric
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 12, 26Jun 12, 2026 | Karas Eric Direct | Sell | $250K$250,000.00 |
| Jun 12, 26Jun 12, 2026 | Fitzpatrick Alexander A Direct | Sell | $33.6K$33,550.00 |
Summary
Insiders reported 0 buys worth $0.00 and 2 sells worth $283,550.00 over the last 12 months. That adds up to net selling of $283,550.00. Karas Eric was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +300.1% | +33.2% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +300.1% over three years. Forward estimates point to Revenue at +33.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does ARS Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about SPRY's management, answered from reported figures.
Who manages SPRY?
ARS Pharmaceuticals, Inc. (SPRY) lists 9 active executives. The top listed executive is Alexander A. Fitzpatrick, Chief Legal Officer & Secretary.
Are SPRY insiders buying or selling?
Recent insider activity shows net buying of $49.44M.
Continue the stock analysis
Jump to another research area for this company.